Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $111.7800 (3.09%) ($106.4400 - $114.5700) on Sat. Nov. 24, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.3% (three month average) | RSI | 29 | Latest Price | $111.7800(3.09%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE declines -8.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting SAGE price | SAGE will decline at least -1.65% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.65% (StdDev 3.3%) | Hourly BBV | 0 () | Intraday Trend | 4.2% | | | |
|
1 - 5 Day Possible Target | $95.52(-14.55%) | Resistance Level | $120.19 | 5 Day Moving Average | $110.3(1.34%) | 10 Day Moving Average | $112.99(-1.07%) | 20 Day Moving Average | $120.19(-7%) | To recent high | -32.2% | To recent low | 4.1% | Market Cap | $N/A | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |